Asset Details
Do you wish to reserve the book?
Potential Cross-Reactive Immunity to SARS-CoV-2 From Common Human Pathogens and Vaccines
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Potential Cross-Reactive Immunity to SARS-CoV-2 From Common Human Pathogens and Vaccines
Do you wish to request the book?
Potential Cross-Reactive Immunity to SARS-CoV-2 From Common Human Pathogens and Vaccines
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Potential Cross-Reactive Immunity to SARS-CoV-2 From Common Human Pathogens and Vaccines
2020
Overview
The recently emerged SARS-CoV-2 causing the ongoing COVID-19 pandemic is particularly virulent in the elderly while children are largely spared. Here, we explored the potential role of cross-reactive immunity acquired from pediatric vaccinations and exposure to common human pathogens in the protection and pathology of COVID-19. To that end, we sought for peptide matches to SARS-CoV-2 (identity ≥ 80%, in at least eight residues) in the proteomes of 25 human pathogens and in vaccine antigens, and subsequently predicted their T and B cell reactivity to identify potential cross-reactive epitopes. We found that viruses subject to pediatric vaccinations do not contain cross-reactive epitopes with SARS-CoV-2, precluding that they can provide any general protection against COVID-19. Likewise, common viruses including rhinovirus, respiratory syncytial virus, influenza virus, and several herpesviruses are also poor or null sources of cross-reactive immunity to SARS-CoV-2, discarding that immunological memory against these viruses can have any general protective or pathological role in COVID-19. In contrast, we found combination vaccines for treating diphtheria, tetanus, and pertussis infectious diseases (DTP vaccine) to be significant sources of potential cross-reactive immunity to SARS-CoV-2. DTP cross-reactive epitopes with SARS-CoV-2 include numerous CD8 and CD4 T cell epitopes with broad population protection coverage and potentially neutralizing B cell epitopes in SARS-CoV-2 Spike protein. Worldwide, children receive several DTP vaccinations, including three-four doses the first year of life and one at 4-6 years of age. Moreover, a low antigenic Tdap dose is also given at ages 9-14. Thereby, children may well be protected from SARS-CoV-2 through cross-reactive immunity elicited by DTP vaccinations, supporting testing in the general population to prevent COVID-19.
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
/ Antigens
/ CD4-Positive T-Lymphocytes - immunology
/ CD8-Positive T-Lymphocytes - immunology
/ Child
/ Children
/ coronavirus disease 19 (COVID-19)
/ COVID-19
/ COVID-19 - prevention & control
/ Diphtheria-Tetanus-Pertussis Vaccine - immunology
/ epitope
/ Epitopes
/ Epitopes, B-Lymphocyte - immunology
/ Epitopes, T-Lymphocyte - immunology
/ Female
/ Genomes
/ Host-Pathogen Interactions - immunology
/ Humans
/ Immunity
/ Infant
/ Male
/ Peptides
/ Proteins
/ Severe acute respiratory syndrome coronavirus 2
/ severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
/ Spike Glycoprotein, Coronavirus - immunology
/ Tetanus
/ Vaccines
